» Articles » PMID: 26372038

Immunotherapies for Bladder Cancer: a New Hope

Overview
Journal Curr Opin Urol
Specialty Urology
Date 2015 Sep 16
PMID 26372038
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose Of Review: We review recent data on immunotherapies for bladder cancer and discuss strategies to maximize the antitumor effect of immunotherapy in solid tumors.

Recent Findings: Anti-programmed death ligand 1 has shown promise in advanced bladder cancer. Clinical trials of immune checkpoint inhibitors as monotherapy or in combination are underway. Here we review strategies for enhancing antitumor immunity using immunomodulating agents or combination treatments that may increase tumor response.

Summary: Combining immune checkpoint inhibitors with other treatment modalities may lead to the development of new treatment strategies in advanced bladder cancer; however, identifying predictive biomarkers is essential for appropriate patient selection.

Citing Articles

Immunobiology of cancer stem cells and their immunoevasion mechanisms.

Marzban H, Pedram N, Amini P, Gholampour Y, Saranjam N, Moradi S Mol Biol Rep. 2023; 50(11):9559-9573.

PMID: 37776412 DOI: 10.1007/s11033-023-08768-9.


Specific subsets of urothelial bladder carcinoma infiltrating T cells associated with poor prognosis.

Guo R, Wang L, Bai S, Kang D, Zhang W, Ding Z Sci Rep. 2023; 13(1):12801.

PMID: 37550396 PMC: 10406853. DOI: 10.1038/s41598-023-39208-0.


NKG2A and circulating extracellular vesicles are key regulators of natural killer cell activity in prostate cancer after prostatectomy.

Lu Y, Ho C, Hong J, Kuo M, Liao Y, Jaw F Mol Oncol. 2023; 17(8):1613-1627.

PMID: 36931723 PMC: 10399716. DOI: 10.1002/1878-0261.13422.


MTHFD2 is a potential oncogene for its strong association with poor prognosis and high level of immune infiltrates in urothelial carcinomas of bladder.

Zhu L, Liu X, Zhang W, Hu H, Wang Q, Xu K BMC Cancer. 2022; 22(1):556.

PMID: 35581573 PMC: 9112551. DOI: 10.1186/s12885-022-09606-0.


Cellular Immunotherapy Targeting Cancer Stem Cells: Preclinical Evidence and Clinical Perspective.

Donini C, Rotolo R, Proment A, Aglietta M, Sangiolo D, Leuci V Cells. 2021; 10(3).

PMID: 33806296 PMC: 8001974. DOI: 10.3390/cells10030543.


References
1.
Xylinas E, Robinson B, Kluth L, Volkmer B, Hautmann R, Kufer R . Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. Eur J Surg Oncol. 2013; 40(1):121-7. DOI: 10.1016/j.ejso.2013.08.023. View

2.
Sugamura K, Ishii N, Weinberg A . Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol. 2004; 4(6):420-31. DOI: 10.1038/nri1371. View

3.
Auchincloss H, Turka L . CTLA-4: not all costimulation is stimulatory. J Immunol. 2011; 187(7):3457-8. PMC: 3178888. DOI: 10.4049/jimmunol.1102316. View

4.
Malmstrom P, Sylvester R, Crawford D, Friedrich M, Krege S, Rintala E . An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol. 2009; 56(2):247-56. DOI: 10.1016/j.eururo.2009.04.038. View

5.
Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View